Page 21 - 南京医科大学学报自然科学版
P. 21
第43卷第5期 刘思远,陈 琳,夏安亮,等. 嵌合抗原受体NK细胞治疗肝细胞癌的研究进展[J].
2023年5月 南京医科大学学报(自然科学版),2023,43(5):595-603,647 ·603 ·
sis[J]. Biomed Res Int,2017,2017:5019367 and checkpoint blockade[J]. Cancer Res,2017,77(24):
[41] CHEN Z N,MI L,XU J,et al. Targeting radioimmunother⁃ 7059-7071
apy of hepatocellular carcinoma with iodine(131 Ⅰ ) [53] CAMMAROTA A,ZANUSO V,D’ALESSIO A,et al.
metuximab injection:clinical phase Ⅰ/Ⅱ trials[J]. Int J Cabozantinib plus atezolizumab for the treatment of ad⁃
Radiat Oncol Biol Phys,2006,65(2):435-444 vanced hepatocellular carcinoma:shedding light on the
[42] HAN Y,SUN F,ZHANG X,et al. CD24 targeting bi⁃spe⁃ preclinical rationale and clinical trials[J]. Expert Opin
cific antibody that simultaneously stimulates NKG2D en⁃ Investig Drugs,2022,31(4):401-413
hances the efficacy of cancer immunotherapy[J]. J Can⁃ [54] BANG Y J,GOLAN T,DAHAN L,et al. Ramucirumab
cer Res Clin Oncol,2019,145(5):1179-1190 and durvalumab for previously treated,advanced non ⁃
[43] CADOUX M,CARUSO S,PHAM S,et al. Expression of small ⁃ cell lung cancer,gastric/gastro ⁃ oesophageal junc⁃
NKG2D ligands is downregulated by beta⁃catenin signal⁃ tion adenocarcinoma,or hepatocellular carcinoma:an
ling and associates with HCC aggressiveness[J]. J Hepa⁃ open⁃label,phase Ia/b study(JVDJ)[J]. Eur J Cancer,
tol,2021,74(6):1386-1397 2020,137:272-284
[44] MANTOVANI S,VARCHETTA S,MELE D,et al. An anti⁃ [55] HSU J,HODGINS J J,MARATHE M,et al. Contribution
MICA/B antibody and IL⁃15 rescue altered NKG2D⁃de⁃ of NK cells to immunotherapy mediated by PD⁃1/PD⁃L1
pendent NK cell responses in hepatocellular carcinoma blockade[J]. J Clin Invest,2018,128(10):4654-4668
[J]. Cancers(Basel),2020,12(12):3583 [56] LIN M,LUO H,LIANG S,et al. Pembrolizumab plus allo⁃
[45] KOHGA K,TAKEHARA T,TATSUMI T,et al. Serum lev⁃ geneic NK cells in advanced non⁃small cell lung cancer
els of soluble major histocompatibility complex(MHC) patients[J]. J Clin Invest,2020,130(5):2560-2569
class I⁃related chain a in patients with chronic liver dis⁃ [57] DAVIS Z,FELICES M,LENVIK T,et al. Low⁃density PD⁃
eases and changes during transcatheter arterial emboliza⁃ 1 expression on resting human natural killer cells is func⁃
tion for hepatocellular carcinoma[J]. Cancer Sci,2008, tional and upregulated after transplantation[J]. Blood
99(8):1643-1649 Adv,2021,5(4):1069-1080
[46] LEE H H,KIM D,JUNG J,et al. NLRP3 deficiency in he⁃ [58] KAMIYA T,SEOW S V,WONG D,et al. Blocking expres⁃
patocellular carcinoma enhances surveillance of NK ⁃ 92 sion of inhibitory receptor NKG2A overcomes tumor resis⁃
through a modulation of MICA/B[J]. Int J Mol Sci,2021, tance to NK cells[J]. J Clin Invest,2019,129(5):2094-
22(17):9285 2106
[47] KAMIMURA H,YAMAGIWA S,TSUCHIYA A,et al. Re⁃ [59] ANDRE P,DENIS C,SOULAS C,et al. Anti ⁃ NKG2A
duced NKG2D ligand expression in hepatocellular carci⁃ mAb is a checkpoint inhibitor that promotes anti ⁃ tumor
noma correlates with early recurrence[J]. J Hepatol, immunity by unleashing both T and NK cells[J]. Cell,
2012,56(2):381-388 2018,175(7):1731-1743
[48] BAUMEISTER S H,MURAD J,WERNER L,et al. Phase [60] JUDGE S J,DUNAI C,AGUILAR E G,et al. Minimal PD⁃
I trial of autologous CAR T cells targeting NKG2D li⁃ 1 expression in mouse and human NK cells under diverse
gands in patients with AML/MDS and multiple myeloma conditions[J]. J Clin Invest,2020,130(6):3051-3068
[J]. Cancer Immunol Res,2019,7(1):100-112 [61] PESCE S,GREPPI M,TABELLINI G,et al. Identification
[49] MURAD J M,BAUMEISTER S H,WERNER L,et al. of a subset of human natural killer cells expressing high
Manufacturing development and clinical production of levels of programmed death 1:a phenotypic and function⁃
NKG2D chimeric antigen receptor⁃expressing T cells for al characterization[J]. J Allergy Clin Immunol,2017,139
autologous adoptive cell therapy[J]. Cytotherapy,2018, (1):335-346
20(7):952-963 [62] TREFNY M P,KAISER M,STANCZAK M A,et al. PD⁃1
[50] WEISS T,WELLER M,GUCKENBERGER M,et al. (+)natural killer cells in human non⁃small cell lung can⁃
NKG2D⁃based CAR T cells and radiotherapy exert syner⁃ cer can be activated by PD⁃1/PD⁃L1 blockade[J]. Cancer
gistic efficacy in glioblastoma[J]. Cancer Res,2018,78 Immunol Immunother,2020,69(8):1505-1517
(4):1031-1043 [63] NIU C,LI M,ZHU S,et al. PD⁃1⁃positive natural killer
[51] MYERS J A,MILLER J S. Exploring the NK cell platform cells have a weaker antitumor function than that of PD⁃1⁃
for cancer immunotherapy[J]. Nat Rev Clin Oncol,2021, negative natural killer cells in lung cancer[J]. Int J Med
18(2):85-100 Sci,2020,17(13):1964-1973
[52] OHS I,DUCIMETIERE L,MARINHO J,et al. Restora⁃ [64] 沙博文,王 曾,周锦仁,等. 洛铂对肝癌肿瘤免疫及
tion of natural killer cell antimetastatic activity by IL12 (下转第647页)